Profile
Sector:
HealthcareIndustry:
Medical DevicesCountry:
United StatesIPO:
22 December 2015Website:
http://www.senseonics.comNext earnings report:
09 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Mon, 01 Jul 2024 23:55:15 GMTDividend
Analysts recommendations
Institutional Ownership
SENS Latest News
MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, today announces that promising new data and analysis results from the SENS-401 following cochlear implantation Phase 2a clinical study will be presented at the 17th International Conference on Cochlear Implants and Other Implantabl.
Senseonics Holdings (SENS) is partnering with Mercy to introduce its Eversense CGM to a healthcare system, which is expected to increase its usage.
Start Time: 16:30 January 1, 0000 5:11 PM ET Senseonics Holdings, Inc. (NYSE:SENS ) Q1 2024 Earnings Conference Call May 13, 2024, 16:30 AM ET Company Participants Tim Goodnow - President and CEO Rick Sullivan - CFO Jeff Ruiz - Head of Strategy and Business Development Philip Taylor - Gilmartin Group, IR Conference Call Participants Marie Thibault - BTIG Colin Clark - Stifel Glenn Shell - Raymond James Matt Taylor - Jefferies Operator Good afternoon, everyone, and welcome to the Senseonics First Quarter 2024 Earnings Conference Call. All participants will be in a listen-only mode.
Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company specializing in long-term, implantable continuous glucose monitoring systems for individuals with diabetes, has confirmed its attendance at the RBC Capital Markets Global Healthcare Conference and the H.C. Wainwright 2nd Annual BioConnect Investor Conference in New York, NY. Management will be present at the RBC conference.
Senseonics Holdings (SENS) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to loss of $0.01 per share a year ago.
Senseonics Holdings, Inc. (NYSE:SENS ) Q3 2023 Earnings Call Transcript November 9, 2023 4:30 PM ET Company Participants Trip Taylor - IR Tim Goodnow - President and CEO Rick Sullivan - CFO Mukul Jain - COO Conference Call Participants Marie Thibault - BTIG Jayson Bedford - Raymond James Operator Good day and welcome to the Senseonics Third Quarter 2023 Earnings Conference Call. All participants will be in listen-only mode.
Senseonics Holdings (SENS) came out with a quarterly loss of $0.04 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.03 per share a year ago.
Senseonics Holdings, Inc. (NYSE:SENS ) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants Philip Taylor - IR Tim Goodnow - President and CEO Rick Sullivan - CFO Conference Call Participants Colin Clark - Stifel Sam Eiber - BTIG Jayson Bedford - Raymond James Operator Good day, and welcome to the Senseonics Second Quarter 2023 Earnings Conference Call. [Operator Instructions] Please note this event is being recorded.
If you're looking to buy penny stocks right now, you've got your work cut out for you. The massive volatility in the stock market today is unlike what many have seen in recent years.
Shares of medical technology company Senseonics Holdings Inc. SENS, -0.52% gained 6.7% premarket on Friday after the company announced that UnitedHealth Group Inc.'s UNH, +1.31% UnitedHealthcare, a major health insurer, would provide coverage of its implantable continuous glucose monitoring system. The coverage of the Eversense E3 CGM System will start July 1 for people with type 1 and insulin-requiring type 2 diabetes, Senseonics said in a release.
What type of business is Senseonics Holdings?
Senseonics Holdings, Inc., a medical technology company, develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes in the United States, Europe, the Middle East, and Africa. The company's products include Eversense and Eversense XL, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management for a period of up to six months. It serves healthcare providers and patients through a network of distributors and strategic fulfillment partners. The company has a collaboration agreement with the University Hospitals Accountable Care Organization. Senseonics Holdings, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.
What sector is Senseonics Holdings in?
Senseonics Holdings is in the Healthcare sector
What industry is Senseonics Holdings in?
Senseonics Holdings is in the Medical Devices industry
What country is Senseonics Holdings from?
Senseonics Holdings is headquartered in United States
When did Senseonics Holdings go public?
Senseonics Holdings initial public offering (IPO) was on 22 December 2015
What is Senseonics Holdings website?
https://www.senseonics.com
Is Senseonics Holdings in the S&P 500?
No, Senseonics Holdings is not included in the S&P 500 index
Is Senseonics Holdings in the NASDAQ 100?
No, Senseonics Holdings is not included in the NASDAQ 100 index
Is Senseonics Holdings in the Dow Jones?
No, Senseonics Holdings is not included in the Dow Jones index
When does Senseonics Holdings report earnings?
The next expected earnings date for Senseonics Holdings is 09 August 2024